Zenas BioPharma (ZBIO) Non Operating Income (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Non Operating Income of -$3.6 million for Q1 2026, down 202.39% year-over-year from $3.6 million in Q1 2025, and down 54.63% quarter-over-quarter from -$2.4 million in Q4 2025.
Zenas BioPharma (ZBIO) Non Operating Income (2023 - 2026) Analysis & Trends
Zenas BioPharma's Non Operating Income history runs 4 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 202.39% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 117.54% YoY), while the FY2025 annual figure was $5.2 million, down 28.49% from the prior year.
- Non Operating Income for Q1 2026 stood at -$3.6 million, down from -$2.4 million in the prior quarter.
- The five-year high for Non Operating Income was $3.6 million in Q1 2025, with the low at -$3.6 million in Q1 2026.
- The 4-year median for Non Operating Income is $1.1 million (2025), against an average of $855454.5.
- The sharpest annual moves came in 2024 and 2026: Non Operating Income soared 14962.5% in 2024, then sank 202.39% in 2026.
- Zenas BioPharma's Non Operating Income stood at $493000.0 in 2023, then jumped by 599.39% to $3.4 million in 2024, then plunged by 168.21% to -$2.4 million in 2025, then sank by 54.63% to -$3.6 million in 2026.
- Business Quant data shows ZBIO's Non Operating Income at -$3.6 million in Q1 2026, -$2.4 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | -3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.68 Mn |
| Mar 31, 2026 | -3.64 Mn |
| Dec 31, 2025 | -2.35 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 2.96 Mn |
| Mar 31, 2025 | 3.55 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | -222,000.00 |
| Dec 31, 2023 | 493,000.00 |
| Sep 30, 2023 | -16,000.00 |